Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lichtenberg

Showing results (131-140 of 2,086) with videos related to

Pageof 209
Sort By:
Health Economics|May 14, 2021
Are drug prices subject to creative destruction? Evidence from the US, 1997-2017Frank R Lichtenberg
The American Journal of Managed Care|February 11, 2005
The effect of access restrictions on the vintage of drugs used by Medicaid enrolleesFrank R Lichtenberg
Forum for Health Economics & Policy|August 30, 2022
The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998-2015Frank R Lichtenberg
Nature Medicine|March 9, 2011
Despite steep costs, payments for new cancer drugs make economic senseFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2015
The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012Frank R Lichtenberg
The Public Policy and Aging Report|April 15, 2016
New Approaches to Preventing Financial Exploitation: A Focus on the BanksPeter A Lichtenberg
The International Journal of Psycho-Analysis|September 9, 1999
Listening, understanding and interpreting: reflections on complexityJ D Lichtenberg
The American Economic Review|April 7, 1996
Do (more and better) drugs keep people out of hospitals?F R Lichtenberg
Forum for Health Economics & Policy|April 25, 2019
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects AnalysisFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2011
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007Frank R Lichtenberg
Pageof 209

Showing results (131-140 of 2,086) with videos related to

Sort By:
Pageof 209
Health Economics|May 14, 2021
Are drug prices subject to creative destruction? Evidence from the US, 1997-2017Frank R Lichtenberg
The American Journal of Managed Care|February 11, 2005
The effect of access restrictions on the vintage of drugs used by Medicaid enrolleesFrank R Lichtenberg
Forum for Health Economics & Policy|August 30, 2022
The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998-2015Frank R Lichtenberg
Nature Medicine|March 9, 2011
Despite steep costs, payments for new cancer drugs make economic senseFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2015
The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012Frank R Lichtenberg
The Public Policy and Aging Report|April 15, 2016
New Approaches to Preventing Financial Exploitation: A Focus on the BanksPeter A Lichtenberg
The International Journal of Psycho-Analysis|September 9, 1999
Listening, understanding and interpreting: reflections on complexityJ D Lichtenberg
The American Economic Review|April 7, 1996
Do (more and better) drugs keep people out of hospitals?F R Lichtenberg
Forum for Health Economics & Policy|April 25, 2019
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects AnalysisFrank R Lichtenberg
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2011
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007Frank R Lichtenberg
Pageof 209